Related Experiment Video
Updated: Jun 7, 2026
10:15
The Use of the Ex Vivo Chandler Loop Apparatus to Assess the Biocompatibility of Modified Polymeric Blood Conduits
Published on: August 20, 2014
11.6K
Tolerating CD47
Jeffrey S Isenberg1, Enrique Montero2
1Department of Diabetes Complications & Metabolism, Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Clinical and Translational Medicine
|February 16, 2024
Summary
Cluster of differentiation 47 (CD47) is a cell surface protein with complex roles in cell interactions. Understanding its dual functions is key to developing new therapies for cancer and autoimmune diseases.
Area of Science:
- Immunology
- Cell Biology
- Drug Development
Background:
- Cluster of differentiation 47 (CD47) is a cell surface protein involved in cell-cell interactions.
- CD47 plays a role in immune responses and is a target for drug development.
- Previous clinical trials of CD47-blocking antibodies have faced setbacks.
Purpose of the Study:
- To explore the complex and seemingly conflicting roles of CD47.
- To investigate the therapeutic potential of modulating CD47 activity.
- To consider implications for autoimmune diseases and cancer.
Main Methods:
- Review of existing literature on CD47.
- Analysis of CD47's position as a junction for receptor-ligand interactions.
- Consideration of signaling pathways influenced by CD47.
Main Results:
- CD47 exhibits pleiotropic effects due to its extensive receptor-multiligand network.
- On-target effects of CD47 modulation are often overlooked.
- CD47's dual role as a connector of receptors and signaling pathways impacts various cell types.
Conclusions:
- The clinical utility of CD47 modulation (both blocking and boosting) requires further investigation.
- CD47's complex functions present both challenges and opportunities for therapeutic intervention.
- Targeting CD47 may offer potential benefits for autoimmune diseases and cancer treatment.
